期刊文献+

BRAF基因突变对甲状腺乳头状癌(PTC)中央区淋巴结转移的影响 被引量:8

The effects of BRAF gene mutation on PTC lymph node metastasis in central region
下载PDF
导出
摘要 目的:探讨BRAF基因突变对甲状腺乳头状癌(PTC)中央区淋巴结转移的相关性因素,着重研究BRAF基因突变中不同肿瘤直径对PTC的影响。方法:回顾性分析本院甲状腺外科2011年10月-2013年10月2年间手术切除的136例PTC病例,分析BRAF基因突变与相关因素之间的关系。结果:PTC中BRAF基因突变率为69.85%(95/136)。BRAF基因突变阳性者颈部中央区淋巴结转移率为34.74%(33/95),BRAF基因突变阴性者中央区淋巴结转移率为12.2%(5/41),两者统计学差异具有相关性(P<0.05)。肿瘤直径大于2cm时BRAF基因突变率为90.48%(19/21),直径小于等于2cm时BRAF基因突变率为66.09%(76/115),两者统计学差异具有相关性(P<0.05)。结论:BRAF基因突变与PTC中央区淋巴结转移存在相关性。对于术前检测BRAF突变阳性的病例,当肿瘤直径大于2cm时应该常规清扫该中央区淋巴脂肪组织。 Objective:To investigate the effect of BRAF gene mutation on PTC central lymph node metastasis.Methods:To retrospectively analyze data of 136 cases of resected cases of PTC.Results:In PTC the BRAF gene mutation rate was 69.85% % (95/136).In BRAF mutation-positive cervical lymph node metastasis was 34.74% (33/95),in BRAF mutation-negative lymph nodes 12.2% (5/41) (P < 0.05).When tumor diameter was greater than 2cm BRAF gene mutation was 90.48% (19/21),the diameter of 2cm or less,the BRAF gene mutation rate was 66.09% (76/115) (P < 0.05).Conclusion:There is a correlation between BRAF gene mutation in papillary thyroid carcinoma with lymph node metastasis in the central area.
出处 《现代肿瘤医学》 CAS 2015年第2期189-191,共3页 Journal of Modern Oncology
基金 黑龙江省自然科学基金(编号:D201228) 哈尔滨医科大学附属二院青年基金(编号:QN2012-07)
关键词 甲状腺乳头状癌 BRAF基因 基因突变 淋巴结转移 papillary thyroid carcinoma BRAF gene mutation lymph node metastases
  • 相关文献

参考文献16

  • 1Xing M.Prognostic utility of BRAF mutation in papillary thyroid cancer[J].Mol Cell Endocrinol,2010,321(1):86-93.
  • 2郑莹,吴春晓,金凡,顾凯,鲍萍萍,王春芳,卢伟.上海市区1973至2005年癌症的发病趋势[J].诊断学理论与实践,2009,8(1):25-32. 被引量:69
  • 3Montero PH,Ibrahimpasic T,Nixon IJ,et al.Thyroid metastasectomy[J].J Surg Oncol,2014,109(1):36-41.
  • 4吴恢升,何劲松,陈伟财,王先明.选择性颈淋巴结清除术在乳头状甲状腺癌手术治疗的临床应用[J].中国普通外科杂志,2012,21(5):532-535. 被引量:17
  • 5Chakraborty A,Narkar A,Mukhopadhyaya R,et al.BRAFV600E mutation in papillary thyroid carcinoma:Significant association with node metastases and extra thyroidal s'invasion[J].Endocr Pathol,2012,23(2):83-93.
  • 6Lee X,Gao M,Ji Y,et al.Analysis of differential BRAFV600E mutational status in high aggressive papillary thyroid microcarcinoma[J].Ann Surg Oncol,2009,16(2):240-245.
  • 7Kondo T,Ezzat S,Asa SL.Pathogenetic mechanisms in thyroid follicular-cell neoplasia[J].Nature Reviews Cancer,2006,6(4):292-306.
  • 8Kim SW,In Lee J,Kim JW,et al.BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule:A large series in a BRAFV600E-prevalent population[J].J Clin Endocrinol Meta,2010,95(8):3693-3700.
  • 9Xing M,Alzahrani AS,Carson KA,et al.Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer[J].JAMA,2013,309(14):1493-1501.
  • 10Kim S,Lee KE,Myong JP,et al.BRAFV600E mutation is associated with tumor aggressiveness in papillary thyroid cancer[J].World J Surg,2012,36(2):310-317.

二级参考文献46

共引文献98

同被引文献91

引证文献8

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部